(Q33845434)

29 July 2017

1 reference

title

Intravesical therapy for bladder cancer (English)

1 reference

29 July 2017

Kamat AM

1

1 reference

PubMed ID

10688071

29 July 2017

Lamm DL

series ordinal

2

1 reference

PubMed ID

10688071

29 July 2017

language of work or name

English

0 references

publication date

1 February 2000

1 reference

29 July 2017

1 reference

29 July 2017

55

1 reference

29 July 2017

2

1 reference

29 July 2017

161-168

1 reference

Requirement of a thymus dependent immune response for BCG-mediated antitumor activity

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

The role of nitric oxide in bacillus Calmette-Guérin mediated anti-tumour effects in human bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Experience with intravesical bacillus Calmette-Guèrin therapy of superficial bladder tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Intravesical bacillus Calmette-Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Primary bladder carcinoma in situ: assessment of early BCG response as a prognostic factor

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Intravesical bacille Calmette-Guérin therapy for muscle invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Results of 6 Weekly Intravesical Bacillus Calmette-Guerin Instillations on the Treatment of Superficial Bladder Tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Megadose vitamins in bladder cancer: a double-blind clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Bacillus Calmette-Guérin treatment and vesicorenal reflux

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Superficial bladder cancer: the role of interferon-alpha.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Transurethral resection with perioperative instilation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study--Finnbladder III

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

A randomized study of short-versus long-term intravesical epirubicin instillation for superficial bladder cancer. Nagoya University Urological Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: a long-term experience

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary ca

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Follow-up of patients with "superficial" transitional cell carcinoma of the bladder: the case for a change in policy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Carcinoma in situ as a prognostic factor for G3pT1 bladder tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Intravesical therapy for transitional cell carcinoma of the bladder: the community practice

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Bladder cancer, 1996.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese Urological Cancer Research Group for Adriamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

Association of in vitro growth potential of urinary exfoliated cells with tumor localization and intraluminal recurrence rates of urothelial cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900463-X

7 January 2021

10.1016/S0090-4295(99)00463-X

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10688071